In line with this, recent real-world studies of treatment with Tofersen in SOD1 ALS patients showed a marked decline of serum NfL as well as CSF pNfH mirroring clinical disease stabilization (Wiesenfarth et al., 2024; Smith et al., 2025). The gene discussed is NEFL; the disease is amyotrophic lateral sclerosis.